Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Joe Y. Chang(The University of Texas MD Anderson Cancer Center), Suresh Senan(Amsterdam UMC Location VUmc), Marinus A. Paul(Amsterdam UMC Location VUmc), Reza J. Mehran(The University of Texas MD Anderson Cancer Center), Alexander V. Louie(Amsterdam UMC Location VUmc), Peter Balter(The University of Texas MD Anderson Cancer Center), Harry J.M. Groen(University Medical Center Groningen), Stephen E. McRae(The University of Texas MD Anderson Cancer Center), Joachim Widder(University Medical Center Groningen), Lei Feng(The University of Texas MD Anderson Cancer Center), Ben E.E.M. van den Borne(Catharina Ziekenhuis), Mark F. Munsell(The University of Texas MD Anderson Cancer Center), Coen Hurkmans(Catharina Ziekenhuis), Donald A. Berry(The University of Texas MD Anderson Cancer Center), Erik van Werkhoven(The Netherlands Cancer Institute), John J. Kresl(Phoenix (United States)), Anne‐Marie C. Dingemans(Maastricht University), Omar Thanoon Dawood(Bellevue Hospital Center), Cornelis J.A. Haasbeek(Amsterdam UMC Location VUmc), L.Steven Carpenter(Saint Luke's Health System), Katrien De Jaeger(Catharina Ziekenhuis), Ritsuko Komaki(The University of Texas MD Anderson Cancer Center), Ben J. Slotman(Amsterdam UMC Location VUmc), Egbert F. Smit(Amsterdam UMC Location VUmc), Jack A. Roth(The University of Texas MD Anderson Cancer Center)
The Lancet Oncology
May 13, 2015
Cited by 1,459Open Access
Full Text

Abstract


Related Papers